PRRTInfo.org - A Resource for Patients Considering PRRT Treatment.
PRRTinfo.org is a site for patients considering PRRT (Peptide Receptor Radionuclide Therapy) treatment in Germany written by patients for patients. While much of this information can be used by patients seeking treatment at any PRRT Center worldwide, this site focus is on the treatment as provided by Dr. Richard Baum and his team at the Zentralklinik Bad Berka in Bad Berka, Germany. We also provide links to a select number of other medical centers that offer PRRT which can be found here.
As with any site that offers information on treatment or travel, please confirm medical information with your medical team, as well as any travel information with the travel providers.
We look forward to your feedback.
The results from the first randomized control trial of PRRT were released today in Vienna, Austria showing increased progression free survival compared to high dose octreotide LAR.
PRRT while available in many parts of the world has not yet been approved for use pending prospective randomized clinical trails (RCT). Having a positive RCT for PRRT will greatly expand access and availability to PRRT around the world. Click here to download the full release.
At the 2nd Theranostics World Congress there was progress towards the treatment of metastatic prostate cancer using a Theranostics approach. At the 3rd Theranostics World Congress that progress continued from the bench and to the bedside.
This video is an overview of the treatment and management of metastatic prostate cancer using a Theranostic Approach.
Dosimetry is used by many centers that preform PRRT. Wikipedia defines Dosimetry as "the measurement of the absorbed dose delivered by ionizing radiation, the term is better known as a scientific sub-specialty in the fields of health physics and medical physics, where it is the calculation and assessment of the radiation dose received by the human body."
Below is a talk given by Christiane Schuchardt on how the Theranostics Center in Bad Berka use dosimetry in there daily patient management.
For the second year in a row, NorCal CarciNET Community and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a patient education day during the SNMMI's Annual Meeting. The program took place on June 8th and began with three (3) general lectures about the definition of nuclear medicine and molecular imaging, safety of nuclear medicine, the value of patient and physician partnerships in care management. The afternoon concluded with breakout sessions focused on hot topics in colon cancer, prostate cancer, thyroid diseases, and neuroendocrine tumors. The total number of attendees was 120 with over 50 attending the NET breakout. To see the complete program and recordings of the breakout sessions, visitwww.snmmi.org/PED. The NET sessions are available below.
Ga-68-labeled somatostatin analogs are important imaging agents to detect and manage neuroendocrine tumors (NETs). The SNMMI formed the 68Ga Users Group to advance the use of these imaging agents in the US. Members of the Users Group developed harmonized release criteria, an imaging manual, generic data collection forms and a draft informed consent form to aid the community in establishing investigator-sponsored trials. In October 2013, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) received orphan drug designation for Ga-68 DOTATOC.